Biotech Values

[DewDiligence]

Here are the remaining 2006 events on our
clinical/regulatory calendar. If anyone knows
that something here is wrong, please chime in.

AMGN – Vectibix final OS from ‘408’ study.

ANOR, AOM.TO – pivotal AMD3100 results.

COLY – 12-week interim data from the lead Actilon trial, the phase-2 for null responders.

CORT – Phase-3 ‘06’ trial of Corlux for psychotic major depression.

GILD – Start phase-1 for GS9190 in HCV.

GTCB – Start phase-2 ATryn trial in DIC by Leo Pharma.

NRMX, NRM.TO – Complete enrollment in European Alzhemed trial.

YMI – AeroLEF final results.